In late 2018, the Novacap group unified all its subsidiaries into a new brand to become SEQENS, an integrated global leader in pharmaceutical synthesis and specialty ingredients for delivering unrivalled market responsiveness and tailor-made solutions to their customers. Operating in 36 industrial plants, R&D centers and commercial offices worldwide with over 3,200 employees in total, SEQENS experts support the development, scale-up and manufacturing of drug substances from preclinical through commercial phase. SEQENS offers a large portfolio of APIs, development and manufacturing of proprietary products, materials for medical and health imaging, and development of custom solutions and ingredients for industries such as healthcare, electronics, cosmetics, food and homecare.